

Supplementary material BMJ Open


**1a.** Official negotiated price (ex-factory) vs percentage improvement in median Overall Survival (OS) (16 drugs are included in the analysis: 15 with a single indication and one with two indications)



**1b.** Official negotiated price (ex-factory) vs percentage improvement in median Progression Free Survival (PFS) (25 drugs are included in the analysis: 22 with a single indication, two with two indications and one with three indication)



**1c.** Official negotiated price (ex-factory) vs percentage improvement in proportion of Objective Response Rate (ORR) (24 drugs are included in the analysis: 20 with a single indication, three with two indications and one with three indications)



Progression Free Survival (PFS); Overall Survival (OS); Objective Response Rate (ORR)